PA Inhibitors
1 drugsAbout PA
The mechanism of action of PA is not specified in the provided data.
There is currently no genetic evidence available linking PA to specific diseases, limiting understanding of its direct role in disease pathology.
PA is targeted by one FDA-approved antibody drug, ANTHIM, developed by ELUSYS THERAPEUTICS INC for an 'Other' therapeutic area.
Top PA Drugs
ELUSYS THERAPEUTICS INC is the only company with an approved drug targeting PA.
The market is not competitive, representing a high barrier to entry.
PA Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PA, using antibody modality.
Consider exploring alternative modalities to differentiate from existing therapies.
PA Clinical Trials 2 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PA. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
PA Drug Approval Timeline (2016 - 2016)
ANTHIM was approved in 2016 and remains the only approved drug.
The approval timeline indicates a potentially unsaturated market with room for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PA. A trial counts if an approved drug acting on PA is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.